We investigated the efficacy of dolutegravir/lamivudine for maintenance treatment for people with HIV and previous lamivudine resistance.

Switching to a two-drug regimen of dolutegravir / lamivudine (Dovato) resulted in significantly less weight gain after 96 weeks compared to a switch to tenofovir alafenamide / emtricitabine / bictegra...

Reducing the number of active compounds for lifelong human immunodeficiency virus (HIV) treatment is of interest, especially to reduce potential long-term side effects.

Through 144 weeks in GEMINI-1/-2 and 48 weeks in STAT, dolutegravir/lamivudine demonstrated high rates of virologic efficacy and a good safety profile in individuals naive to antiretroviral therapy across baseline viral load categories, including in those with very high baseline viral load (>500,000 copies/mL). ClinicalTrials.gov: NCT02831673/NCT02831764; NCT03945981.

This post hoc analysis evaluated dolutegravir/lamivudine efficacy and safety by baseline viral load (VL) categories in participants naive to antiretroviral

A study in CID investigated dolutegravir/lamivudine for maintenance treatment for people with HIV and previous lamivudine resistance. Read IDSA’s Journal Club review by Erica Kaufman West, MD, FACP, F...

Dolutegravir/Lamivudine demonstrated efficacy and safety as initial ART in adolescents with HIV-1 through 48 weeks.

Tenofovir/lamivudine/dolutegravir (TLD) is widely prescribed worldwide. We report virologic and resistance outcomes for patients initiating or switching to TLD.

This randomized clinical trial compares the effects of a regimen with doravirine, lamivudine, and tenofovir disoproxil fumarate vs a regimen with dolutegravir, emtricitabine, and tenofovir alafenamide...

Having a hidden infection with hepatitis B may undermine viral suppression after a switch to dolutegravir / lamivudine (Dovato), a study of people with HIV who simplified treatment in Italian and Fren...

In the first randomized, head-to-head trial in adults initiating antiretroviral therapy, dolutegravir/lamivudine demonstrated non-inferior efficacy to bict

An initial trial suggests lamivudine, an inexpensive oral drug for treating HIV, can improve vision in patients with diabetic macular edema more effectively and affordably than current therapies.

Through 144 weeks in GEMINI-1/-2 and 48 weeks in STAT, dolutegravir/lamivudine demonstrated high rates of virologic efficacy and a good safety profile in individuals naive to antiretroviral therapy across baseline viral load categories, including in those with very high baseline viral load (>500,000 copies/mL). ClinicalTrials.gov: NCT02831673/NCT02831764; NCT03945981.

Background Antiretroviral therapy (ART) in people with HIV (PWH) can lead to weight gain, but the effects of nucleoside reverse transcriptase inhibitors such as abacavir (ABC) are not well understood....